Can N‑butyl cyanoacrylate (NBCA) be used instead of Setrol (polidocanol) for endoscopic sclerotherapy of esophageal varices?

N-Butyl Cyanoacrylate Should NOT Replace Setrol (Polidocanol) for Esophageal Varices

For esophageal varices specifically, variceal band ligation is the first-line treatment, and if unavailable, traditional sclerotherapy with agents like polidocanol (Setrol) should be used—N-butyl cyanoacrylate (NBCA) is NOT indicated for esophageal varices and is reserved for gastric (cardiofundal) varices only. 1, 2, 3

The Critical Distinction: Location Matters

The evidence clearly delineates treatment based on varix location:

For Esophageal Varices:

• First choice: Variceal band ligation (Grade AI recommendation) 1
• If banding unavailable: Endoscopic sclerotherapy with traditional sclerosants like polidocanol (Grade BI recommendation) 1
• The sclerosant used may vary between institutions 1, but NBCA is not mentioned as an option for esophageal varices in guidelines

For Gastric Varices (GOV2, IGV1):

• NBCA (cyanoacrylate) is specifically indicated for gastric/cardiofundal varices 1, 2, 3
• Studies show NBCA achieves 90% control of active bleeding from gastric varices 1
• NBCA demonstrated significantly higher initial bleeding control and improved survival compared to traditional sclerotherapy for gastric varices 1

Why This Distinction Exists

Anatomical and hemodynamic differences between esophageal and gastric varices explain the treatment divergence:

• Esophageal varices respond well to band ligation and traditional sclerosants due to their anatomy and flow characteristics
• Gastric varices, particularly fundal varices, have different vascular architecture requiring tissue adhesives like NBCA for effective obliteration 1, 2

Evidence Supporting Combined Use (Not Replacement)

Research shows that when NBCA is used for esophageal varices, it's typically combined with polidocanol, not used as a replacement 4:

• A 1995 randomized study found that NBCA plus polidocanol sclerotherapy reduced rebleeding (2/20 vs 8/18, p<0.05) and mortality (3/21 vs 9/18, p<0.05) compared to polidocanol alone in patients with active bleeding 4
• A 1997 prospective study used NBCA plus polidocanol for grade 4 varices and large solitary varices, while using polidocanol alone for grades 1-3 esophageal varices 5

Critical Safety Concerns with NBCA

NBCA carries specific risks that make it unsuitable as a routine esophageal variceal sclerosant:

• Cerebral embolism: Recent 2025 case report documented stroke from NBCA migration via portopulmonary venous anastomosis after endoscopic injection 6
• Systemic embolization risk: NBCA can migrate through collateral pathways even without patent foramen ovale 6
• Technical expertise required: NBCA requires specialized training and is not approved for gastric varices in the United States 3
• Equipment damage: Can damage endoscopes if not used properly

Setrol (Polidocanol) Safety Profile

Setrol has a well-established safety profile for esophageal sclerotherapy 7, 8:

• Superior safety compared to sodium tetradecyl sulfate and hypertonic saline 8
• Main complications: local reactions (pain, ulceration), tissue necrosis with extravasation 7
• Rare but serious: anaphylaxis (at least 4 deaths reported historically) 7
• Precaution: Test dose of 0.5 mL recommended before full treatment 7

Common Pitfalls to Avoid

1. Do not use NBCA for routine esophageal varices—it's not indicated and carries unnecessary embolic risks
2. Do not confuse gastric and esophageal varix management—they require different approaches
3. Do not use NBCA without proper training—it requires specialized technique
4. Always prioritize band ligation when available for esophageal varices 1, 2

Clinical Algorithm

For acute esophageal variceal bleeding:

1. Start vasoactive drugs + antibiotics immediately
2. Perform endoscopy within 12 hours
3. If esophageal varices identified:
   • First choice: Band ligation
   • If banding not feasible: Polidocanol sclerotherapy
   • Continue vasoactive drugs for 3-5 days 2

For gastric varices (GOV2/IGV1):

1. Consider TIPS as first-line 3
2. If TIPS not feasible: NBCA injection (where available and expertise exists)

The answer is clear: NBCA should not replace Setrol for esophageal varices—they serve different anatomical targets, with NBCA reserved for gastric varices where its unique tissue adhesive properties are necessary.